Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.
Frequently asked questions
What sector does Ribomic Inc (4591) operate in?
Ribomic Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ribomic Inc (4591) current stock price?
As of the latest data, Ribomic Inc stock price is ¥76, with a previous close of ¥76.
What is Ribomic Inc (4591) current market capitalization?
Ribomic Inc market cap is approximately 4.25 billion.
What is Ribomic Inc (4591) Earnings Per Share (EPS)?
The trailing EPS is -¥23.
What is Ribomic Inc (4591) EBITDA?
Ribomic Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -418.01 million.
Does Ribomic Inc (4591) pay dividends?
No. Ribomic Inc does not pay a dividend.
What is Ribomic Inc (4591) beta (volatility) score?
Ribomic Inc has a beta of 0.200, indicating lower volatility than the overall market.
